Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 double-blind placebo-controlled trial of solithromycin for Mycoplasma genitalium infection
jRCT2031250109Phase 2Recruiting
- Start
- Jul 2025
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of solithromycin in Mycoplasma genitalium infection (Mgen) (3 arms). Primary endpoint: Bacteriological efficacy at TOC. Started Jul 2025; status: recruiting.
02
Drugs
solithromycin
03
Conditions
Mycoplasma genitalium infection (Mgen)
Beyond the preview
Go deeper on jRCT2031250109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250109.